10/31/2024 5:28 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/31/2024 5:19 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/31/2024 5:21 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/26/2024 5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/22/2024 7:36 PM | Platford Giles Richard (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/31/2024 6:46 AM | Takeda Pharmaceutical (Filed by) Xilio Therapeutics, Inc. (Subject)
| Form SC 13G/A | |
07/31/2024 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
|
07/10/2024 6:12 AM | Amakawa Akiko (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024 6:13 AM | Plump Andrew Stewart (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024 6:13 AM | Takeda Pharmaceutical (Subject) Weber Christophe Pierre (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024 6:14 AM | Shannon Elaine Mary (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024 6:15 AM | Ricci Gabriele (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024 6:15 AM | Platford Giles Richard (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024 6:16 AM | Kim Julie So-Young (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024 6:16 AM | Duprey Lauren Rusckowski (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024 6:17 AM | Pignagnoli Agosti Marcello (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024 6:17 AM | Sequeira Ramona (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024 6:18 AM | Bitetti Teresa Marie (Reporting) Takeda Pharmaceutical (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024 6:19 AM | Takeda Pharmaceutical (Subject) Wozniewski Thomas Otto Claus (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/10/2024 5:04 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/09/2024 5:05 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/05/2024 10:28 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/02/2024 5:20 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/01/2024 5:33 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/28/2024 7:24 AM | Takeda Pharmaceutical (Subject)
| Form FWP | |
06/28/2024 7:25 AM | Takeda Pharmaceutical (Filer)
| Form 424B2 Transaction specifc information for a delayed shelf offering | |
06/27/2024 5:01 AM | Takeda Pharmaceutical (Filer)
| Form 424B5 | |
06/26/2024 7:26 AM | Takeda Pharmaceutical (Filer)
| Form F-3ASR | |
06/26/2024 5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/26/2024 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/26/2024 5:07 AM | Takeda Pharmaceutical (Filer)
| Form 20-F Registration statement / Annual report / Transition report | |
06/17/2024 5:46 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/11/2024 5:23 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/10/2024 5:10 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/07/2024 5:04 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/07/2024 5:07 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/03/2024 5:45 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/03/2024 5:26 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/29/2024 5:24 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/29/2024 5:29 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/29/2024 5:29 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Musk’s new company could top a trillion? (Ad) The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix…
Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. |
05/29/2024 5:29 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/21/2024 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/09/2024 5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/09/2024 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/09/2024 5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/09/2024 5:04 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/09/2024 5:08 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/25/2024 5:04 AM | Takeda Pharmaceutical (Filer)
| Form SD Specialized Disclosure Report | |
04/19/2024 5:12 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/15/2024 5:02 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/10/2024 5:10 AM | Phathom Pharmaceuticals, Inc. (Subject) Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
04/01/2024 5:15 AM | Phathom Pharmaceuticals, Inc. (Subject) Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
03/27/2024 5:34 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/09/2024 5:03 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/06/2024 8:36 AM | BlackRock Inc. (Filed by) Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/05/2024 5:24 AM | Sumitomo Mitsui Trust Holdings, Inc. (Filed by) Takeda Pharmaceutical (Subject)
| Form SC 13G/A | |
02/02/2024 5:16 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/01/2024 5:18 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/01/2024 5:06 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/25/2024 5:13 AM | Phathom Pharmaceuticals, Inc. (Issuer) Takeda Pharmaceutical (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/25/2024 5:11 AM | Phathom Pharmaceuticals, Inc. (Subject) Takeda Pharmaceutical (Filed by)
| Form SC 13D/A | |
01/19/2024 5:03 AM | Equillium, Inc. (Subject) Takeda Pharmaceutical (Filed by)
| Form SC 13G | |
01/16/2024 5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
12/14/2023 5:01 AM | Takeda Pharmaceutical (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |